Murakami T, Seguchi M, Nakazawa M, Momma K
Department of Pediatric Cardiology, Heart Institute of Japan, Tokyo Women's Medical College, Japan.
Acta Paediatr Jpn. 1997 Aug;39(4):462-5. doi: 10.1111/j.1442-200x.1997.tb03619.x.
Transfusion-associated graft-versus-host disease (TA-GVHD) is a fatal side effect of blood transfusion. The present study describes a case of TA-GVHD in a neonate treated with anti-CD3 monoclonal antibody (OKT3). The patient died of systemic bacterial infection. However, it is suggested that OKT3 suppressed the graft-versus-host reaction due to the improvement in the clinical signs and a change in the human leucocyte antigen (HLA) type on the surface of circulating lymphocytes. A relatively large dose of OKT3 together with steroid pulse therapy and cyclosporin A may be required for the control of TA-GVHD in neonates.
输血相关移植物抗宿主病（TA-GVHD）是输血的一种致命副作用。本研究描述了一例接受抗CD3单克隆抗体（OKT3）治疗的新生儿发生TA-GVHD的病例。该患者死于全身性细菌感染。然而，由于临床症状改善以及循环淋巴细胞表面人类白细胞抗原（HLA）类型的改变，提示OKT3抑制了移植物抗宿主反应。对于控制新生儿的TA-GVHD，可能需要相对大剂量的OKT3联合类固醇脉冲疗法和环孢素A。
